FindTrial
Sign In

ART5803

DRUG3 trials

Sponsors

Arialys Therapeutics, Arialys Australia Pty Ltd

Conditions

Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric DiseaseAnti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)Autoimmune EncephalitisAutoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor AntibodyAutoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)

Phase 1

Phase 1 Study of ART5803 in Healthy Participants
Active, not recruitingNCT06575153
Arialys TherapeuticsAutoimmune Encephalitis
Start: 2024-09-19End: 2026-03-11Updated: 2026-02-06
Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants
Active, not recruitingNCT06753955
Arialys TherapeuticsAutoimmune Encephalitis, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody (Disorder)
Start: 2025-03-18End: 2025-12-24Target: 6Updated: 2025-09-25

Phase 2

A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Antibody-Associated Psychiatric Disease
Not yet recruitingNCT07093333
Arialys Australia Pty LtdAnti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease, Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Autoimmune Encephalitis
Start: 2025-08-01End: 2027-03-30Target: 30Updated: 2025-07-30